Kymera Therapeutics (NasdaqGM:KYMR) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker15Good day, everyone. My name is Kahealani. I will be your conference operator today. At this time, I'd like to welcome you to the Kymera Therapeutics fourth quarter 2025 results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, and if you've joined via the webinar, pl ...

Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights February 26, 2026 © 2026 NOVAVAX. All rights reserved This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate st ...

10700日元，这是中外制药在2月25日创下的股价新高，相较于1990年至2013年长期徘徊的600日元区间，十几年间涨 幅高达16倍。 这一数字背后，是日本乃至亚洲制药行业首个千亿美元市值企业的诞生。截至25日，中外制药市值高达1087 亿美元， 不仅将将拥有240余年历史的武田制药、以及近年来在ADC领域风头无两的第一三共远远甩在身后，更跻身全球药企 前16名，与赛诺菲、再生元等站在同一水平线。 要知道，市值"千亿美元俱乐部"的成员均为欧美跨国巨头，这一顶级阵营中，一直没有亚洲药企的身影。而长久以 来，中外制药的标签也始终是"罗氏子公司"，如今却为我们带来另一重震撼： 日本是全球最早经历深度老龄化与持续医保控费的国家，其国内医药市场规模在长达20年的时间里近乎停滞。正是在 这样的"逆风局"中，中外制药却完成了从罗氏本土代理商到全球创新引擎的转变，其营业利润率更是维持在近50%的 高位。 当中外制药的千亿美元市值里程碑与日本的老龄化剧本、中国的医药产业现状叠加在一起时，一个核心命题浮出水 面：在支付端压力日益增大、创新成本飙升的全球背景下，药企的成长逻辑究竟发生了什么根本性变化？中外制药的 路径，又能为同样 ...

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025 Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for th ...

KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video conference call and webcast today at ...

Snowflake (NYSE:SNOW) Q4 2026 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsBrian Robins - CFOCatherine McCracken - Head of Investor RelationsChirag Ved - VPChristian Kleinerman - EVP of ProductKoji Ikeda - Director and Enterprise Software Equity ResearchMark Murphy - Managing DirectorSanjit Singh - Executive DirectorSridhar Ramaswamy - CEOConference Call ParticipantsAlex Zukin - Managing Director and Senior AnalystBrad Zelnick - Managing Director and Senior US Software Research AnalystBre ...

Key Takeaways Cytokinetics reported a Q4 loss of $1.50 per share as operating expenses climbed year over year.CYTK gained FDA approval for Myqorzo in oHCM, with EU and China nods and Germany launch set for Q2 2026.Cytokinetics ended 2025 with $1.22B in cash as multiple late-stage aficamten studies advance globally.Cytokinetics (CYTK) reported a net loss of $1.50 per share for the fourth quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.48. In the year-ago quarter, the company reported ...

另一家瑞士制药巨头罗氏CEO托马斯·施尼克尔（Thomas Schinecker）在2025年总共获得了1020万瑞士 法郎（约合9075万元人民币）的薪酬。 此外，据法国制药巨头赛诺菲披露的高管薪酬，2025年，该公司CEO韩保罗（Paul Huson）获得总价值 1090万欧元（约合8837万元人民币）的薪酬。 明星减重药司美格鲁肽生产商、丹麦制药巨头诺和诺德经历了艰难的一年。该公司于去年8月更换领导 层，由马齐亚尔·迈克·杜斯塔德（Maziar Mike Doustdar）接替周赋德（Lars Fruergaard Jorgensen）担任 CEO。 诺和诺德年度薪酬报告披露，在杜斯塔德任职的几个月里，他获得了2070万丹麦克朗（约合2246万元人 民币）的薪酬；周赋德在2025年获得了总额近2000万美元的总薪酬（约合1.37亿元人民币），其中包括 一笔价值682万美元的遣散费以及合计超过930万美元的补偿金。 [ 2023至2025年期间，万思瀚的长期激励计划兑现率高达188%，价值1730万瑞士法郎。 ] 当地时间2月24日，阿斯利康的一份备案文件显示，该公司CEO苏博科（Pacal Soriot ...

SAB Biotherapeutics (NasdaqCM:SABS) FY Conference February 25, 2026 08:40 AM ET Company ParticipantsSam J. Reich - CEOConference Call ParticipantsLeland Gershell - Biotechnology AnalystLeland GershellGreat. Thank you, and welcome everyone to our next presenting company here at Oppenheimer's 36th Annual Healthcare Life Sciences Conference. I'm Leland Gershell, one of the Biotech Analysts with the firm. We are gratified and delighted to have with us SAB Biotherapeutics. The ticker is SABS, which we cover with ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBen Taylor - CFO and President of Recursion UKDave Hallett - Chief Scientific OfficerNajat Khan - CEO and PresidentNajat KhanGood morning, everyone, thank you so much for joining us. I want to start by briefly framing where Recursion is today in its journey and evolution. Over the past decade, Recursion has built something truly special, a differentiated platform, pioneering the integration of l ...